Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Head and neck data

Head and neck data

Company Product Phase # Patients Response
Cel-Sci (CVN) Multikine pretreatment II 28 50% R
ImClone

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE